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A critical component of managing oncology patients
is understanding the natural history of their cancer
and identifying those features of the tumor and the
patient that predict the metastatic process and sur-
vival outcome. The clinical behavior of recurrent or
metastatic melanoma is remarkably heterogeneous.
In this issue of the Annals of Surgical Oncology,
Francken, Thompson and colleagues from the Syd-
ney Melanoma Unit have made yet another valuable
contribution to the literature with their assessment of
survival outcomes, and independent predictors of
survival outcomes in patients with recurrent mela-
noma.
1 Most studies of prognostic factors in mela-
noma patients have examined outcomes from the
time of the original diagnosis.
2,3 This study analyzes
prognostic factors predicting metastatic behavior and
survival outcome starting with the time of ﬁrst relapse
at different anatomic sites. The ability to predict
prognosis from the time of relapse is of critical
importance. Better understanding of expected prog-
nosis in patients with recurrent melanoma allows the
clinician to make better choices in disease evaluation
and treatment, and most importantly for the future of
melanoma care, an ability to categorize patients with
recurrent disease into groups with more homoge-
neous prognoses will lead to better design of clinical
trials of systemic therapies, hopefully hastening the
time when we will have more effective therapies for
our patients with advanced disease.
Knowing how to sort through these variables, and
reconcile diﬀerences in results from the literature, can
be a diﬃcult, if not daunting, task. Understanding
that these clinical and pathological factors are but
crude surrogates of more fundamental biological pre-
dictors of melanoma behavior and survival outcomes
would provide the reader with a more unifying con-
ceptual way of thinking about this subject. Thus, we
could partition the factors described in this study by
Francken et al. into three components: (1) the bio-
logical characteristics of the primary melanoma, (2)
the host´s (i.e., patient) systemic responses to contain
metastatic growth (such as immunological responses),
and (3) the ability of a recurrent or metastatic mela-
noma to grow in a particular microenvironment.
Using this conceptual framework, one could cate-
gorize melanoma patients along a gradation of met-
astatic potential for primary melanomas based upon
whether they are well diﬀerentiated and thus would
have a low biological capability for completing the
metastatic cascade and growing in another microen-
vironment or are poorly diﬀerentiated and thus
would have mutational changes that would allow
them to grow in a microenvironment for which they
were not genetically programmed to grow. There is a
large scale of melanoma cell dediﬀerentiation, each
with diﬀering metastatic risk, between these two ex-
tremes. Within this conceptual model, it is evident
that features of a poorly diﬀerentiated primary mel-
anoma — especially melanoma ulceration and high
mitotic rate — would be associated with increased
metastatic risk.
In the publication by Frankel, the site of ﬁrst
recurrence was a valuable focus of their prognostic
factors analysis.
1 Among 873 patients who relapsed
after treatment (between the years 1960 and 2002),
the initial site of recurrence was local in 11%, intra-
lymphatic (or in transit) in 10%, regional lymph
Published online March 5, 2008.
Address correspondence and reprint requests to: Lisa K. Jacobs,
MD; E-mail: ljacob14@jhmi.edu
Published by Springer Science+Business Media, LLC  2008 The Society of
Surgical Oncology, Inc.
Annals of Surgical Oncology 15(5):1280–1281
DOI: 10.1245/s10434-008-9823-3
1280nodes in 34%, and distant in 45% of patients. By far
the most important predictor of survival was location
of the recurrence. Following ﬁrst recurrences, the
median survival time was 1.3 years, and varied widely
according to the site of ﬁrst recurrence. Local recur-
rences had the best prognosis; regional metastases,
distant skin, lymph nodes, and lung metastases were
intermediate; and all other visceral sites had the worst
prognosis. The authors attributed the better prog-
nosis of lung metastases to lead-time bias (due to
more aggressive screening) or due to the beneﬁt of
metastectomy. An additional possibility is that the
metastases that grew in a lung microenvironment
might be more indolent in their growth potential
compared to metastases that select to grow in other
microenvironments, such as liver or brain.
The age of the patient was an independent pre-
dictor of survival outcome in this study and indeed in
almost all studies of melanoma prognosis.
2–4 Survival
was better for patients \50 years of age presenting
with locoregional recurrences, but not for those with
distant metastases. Increasing age may be a simple
but crude surrogate for declining host immunological
factors or other host defense mechanism. It is also
possible that melanoma in the elderly has different
biological characteristics, just as acral lentigo maligna
has a different mutational signature compared to
solar induced melanomas. Thus, primary melanomas
in the elderly tend to have more features of a poorly
differentiated melanoma, have a lower rate of nodal
metastases, but paradoxically, a higher mortality rate
overall.
One of the most interesting ﬁndings in this study
was that the time period during which a recurrence
was diagnosed correlated with survival rates (i.e.,
comparing the 1960–1970 to the 1990–2002 time
periods). This was particularly notable for patients
with distant metastasis. Why were survival rates
increasing as a function of the decade in which they
were diagnosed? Was it better treatment or lead-time
bias because of better staging? Equally interesting
was the observation that the disease-free interval
prior to first relapse was not statistically significant.
For clinical oncologists who are consulting with a
melanoma patient after a ﬁrst relapse, this informa-
tion is vital to formulate: (1) the stage of disease, (2)
the intensity of the metastatic evaluation, (3) the
predicted incidence of metastatic disease, (4) a treat-
ment plan that calibrates the combination and se-
quence of modalities with the biological
aggressiveness of the disease, and (5) predicted sur-
vival rates after treatment when counseling the pa-
tient during follow-up evaluations. Our criteria for
staging melanoma also depend upon knowing the
most relevant predictive or prognostic factors of
survival outcome. For the clinical investigator,
knowing the most independent and dominant prog-
nostic factors is essential in both the design of the
clinical trial and interpreting the results. Only with
this knowledge can one reliably distinguish between
the impact of the treatment under study and the
survival outcome based on the natural history of the
metastatic process that varies among patients.
Otherwise, treatment diﬀerences, or lack thereof, may
be inﬂuenced more by the mix of the patient’s prog-
nostic factors than by the treatment eﬀect being
studied.
The results from Francken, Thompson, and col-
leagues once again demonstrate that the disease we
refer to as ‘‘metastatic melanoma’’ is actually a very
diverse and heterogeneous collection of clinical pre-
sentations. Understanding this heterogeneity and
taking it into account is important to both the mel-
anoma clinician and the melanoma investigator. In
the past, melanoma has been labeled as unpredict-
able. Actually, the opposite is true as we learn to sort
systematically through the multiple characteristics of
a very heterogeneous disease. This article from the
Sydney Melanoma Unit is a valuable step in that
journey to better understand the natural history of
metastatic melanoma.
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